Clinical Trials
16 trialsNCT04188405 2026-05-22
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01746836 2026-03-09
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01570868 2025-12-08
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04070443 2025-11-18
TIPI
Centre Leon Berard
Phase 2 Active not recruiting
NCT06390306 2025-06-03
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Peking University People's Hospital
Recruiting
NCT03576547 2025-05-08
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT06945146 2025-04-25
CAP
Eulji University Hospital
Completed
NCT02398825 2025-01-17
Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Terminated
NCT04160546 2024-12-31
ResToP
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 2 Active not recruiting
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT03807479 2023-09-14
PONS
GWT-TUD GmbH
Phase 2 Terminated
NCT02448095 2022-10-26
Retrospective Evaluation of CML Patients in the National Compassionate Program
Gruppo Italiano Malattie EMatologiche dell'Adulto
Terminated
NCT04709731 2021-02-03
CarPAs
Associazione Italiana Pazienti Leucemia Mieloide Cronica
Phase 2 Unknown
NCT04043676 2019-08-02
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Fundación Teófilo Hernando, Spain
Phase 2 Unknown
NCT02981784 2016-12-05
Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I
Hospices Civils de Lyon
Completed
NCT01549548 2013-03-15
Compassionate Use Ponatinib
OHSU Knight Cancer Institute
No longer available